Genmab (GMAB) said Tuesday that the global net trade sales of Darzalez (daratumumab), as reported by Johnson & Johnson (JNJ), were $3.24 billion in the first quarter.
Genmab receives royalties on the worldwide net sales of Darzalex under the exclusive worldwide license to Johnson & Johnson to develop, manufacture and commercialize daratumumab, the biotechnology company said.
Darzalex net sales also included sales of the subcutaneous product, daratumumab and hyaluronidase-fihj, sold under the tradename Darzalex Faspro in the US, the company said.
Of the total, net trade sales were $1.83 billion in the US and $1.41 billion in the rest of the world, the company said.
Price: 19.44, Change: +0.12, Percent Change: +0.62
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.